Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: DrugBank:APRD00627 (MAP)
 15,705 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Uteroglobin was obtained from 5 day pregnant rabbits and purified to homogeneity by Sephadex G 75 and DEAE-cellulose chromatographies. Progesterone binding to uteroglobin was decreased by lyophilization and enhanced by SH-reducing agents. Dithiothreitol was more effective than dithioerythritol, and beta-mercaptoethanol was only active at 25 to 100 mM concentrations. SH-blocking agents (iodoacetate, iodoacetamide, phydroxymercuribenzoate and, dithiobisnitrobenzoic acid) inhibited binding. In the absence of SH-reducing agents only one in every 500 uteroglobin molecules bound the hormone, whereas under optimal conditions (20 mM dithiothreitol) one in every two molecules bound progesterone. There was no significant difference in equilibrium dissociation constants under these two conditions. Uteroglobin had a relatively high affinity for progesterone (KD=4.1 X 10(-7)M) but a threefold higher affinity for 5alpha-pregnane-3,20-dione (KD=1.3 X 10(-7)M). Estradiol was bound but non-specifically with a very low affinity, and its binding was not enhanced by SH-reducing agents. Hormonal specificity of binding to uteroglobin was different from that of binding to rabbit uterine progesterone receptor. Various synthetic progestagens (chlormadinone acetate, norethisterone, R5020) were bound to the latter but not to the former protein. Diethylstilbestrol had some affinity (15% of that of progesterone) for uteroglobin and no affinity for the progesterone receptor. Uteroglobin incubated in the presence or absence of cofactors (NADH and NADPH) with or without dithiothreitol did not metabolize progesterone.
 ...
PMID:Interaction of uteroglobin with progesterone, 5alphapregnane-3,20-dione and estrogens. 1 Oct 93

This study examines the effects of MPA (medroxyprogesterone acetate) on some of the hepatic enzymes of carbohydrate and lipid metabolism in the rat, and compares these with the effects of cortisol and saline. Levels of reduced nicotinamide adenine dinucleotide phosphate (NADPH) were also measured. Intact mature female Wistar rats with average initial weight of 200 gms were injected with MPA (mO mg/kg IM) once a week for 4 weeks and were sacrificed 3 to 5 days after the last injection. Hydrocortisone (Solu-Cortef [R]) 40 mg/kg IM were given to cortisol-treated animals twice daily for 7 days. The animals were sacrificed 2-4 hours after the last dose was given. Normal saline (0.2 mg. IM) was injected in control animals twice a day. The method of Jellinek, Amako, and Willman was used to analyze NADPH. Liver samples were assayed for various enzymatic activities such as phophofructokinase (PFK); pyruvate kinase (PK), glycerol-3-phosphate dehydrogenase (G3PD), "malic" enzyme (ME), and glucose-6-phosphate dehydrogenase (G6PD). The methods of Colowick and Kaplan were used in enzymatic analyses. Lipogenic stimulation by MPA is indicated by increased levels of G3PD and ME, both of which are implicated in lipogenesis, as well as by NADPH. PFK, PK, and G6PD were all unaffected by the MPA regimen, suggesting that elevation of ME and NADPH activities may reflect increased amino acid conservation. The enzymatic pattern of MPA treatment shows lipogenesis and protein conservation, while that of cortisol regimen shows significantly lower levels of ME, G3PD, and PRK.
 ...
PMID:Some effects of medroxyprogesterone acetate on intermediary metabolism in rat liver. 2 59

Patients with two or more previous spontaneous second trimester abortions and vaginal cytology indicating a poor progestational response in current pregnancies were selected for treatment with Provera (medroxyprogesterone acetate) and/or Delalutin (17 alpha-hydroxyprogesterone caproate). Serum was examined serially for progesterone (P) and estradiol (E) by radioimmunoassay. Serum from 174 untreated patients with no known complications ranging from 6--40 weeks gestation provided normal distribution data. Of 14 progestagen-treated patients, four aborted during the second trimester. These all had chronically low (greater than 50% of observations were less than 1 standard deviation of the normal population) or falling P/E ratios. The rest delivered normal full-term infants although five of the 10 had chronically low P, seven had chronically low P/E ratios, and in one other P/E was falling. Chronically high E contributed to the low P/E ratio in three cases. Thus, these selected cases with poor obstetrical histories demonstrated steroid patterns outside the +/- 1 standard deviation range, although the steroid levels were still within the normal range. Serum progesterone and estradiol analysis may eventually be useful in identifying patients who will best respond to progestagen treatment.
 ...
PMID:Serum progesterone and estradiol in pregnant women selected for progestagen treatment. 4 Sep 14

The effect of monthly injectios of 300 mg Depo-Provera or 150 mg Deladroxone, and of daily oral administration of .5 mg chlormadinone acetate or .3 mg quingestanol acetate on lactation was studied in Egyptian women during the 1st year of lactation. Women receiving Depo-Provera had the highest milk yield, followed by those taking Deladroxone and quingestanol acetate. The milk yields while taking these hormonal preparations were higher than in untreated controls. However, those women taking chlormadinone acetate had lower milk yields than untreated controls. The increased milk yield is probably due to the progestagenic activity, and minimal estrogenicity, of these drugs.
 ...
PMID:Effect of some progestational steroids on lactation in Egyptian women. I. Milk yield during the first year of lactation. 6 Mar 40

The effect of androgen and different progestins on spermatogenesis was studied in young men with subfertility, prostatovesiculitis and haematospermia, and in older men with benign hypertrophy of the prostate. The compounds (testosterone, testosterone oenanthate, ethinyl oestradiol, megestrol acetate, ethinyl norgestrienone and Depo-Provera) were administered intramuscularly, orally or as subcutaneous silastic implants.
 ...
PMID:Steroidal compounds (injectable and implants) affecting spermatogenesis in men. 6 50

Cytosol from human benign hyperplastic and carcinomatous prostatic tissue has been shown to contain a progestin receptor with a dissociation constant of approximately 10(-9) M. The receptor was measured using 3H-labeled R 5020 (17 alpha, 21-dimethyl-19-nor-4,9-pregnadiene-3,20-dione) as ligand. Progesterone, cyproterone acetate, and R 1881 (methyltrienolone) were efficient competitors to R 5020 for binding sites on the receptor whereas testosterone, 5 alpha--dihydrotestosterone, estradiol, cortisol, and several hydroxylated and saturated derivatives of progesterone did not compete. The [3H]R 2020-receptor-complex had a sedimentation coefficient of approximately 4 S, an isoelectric point of approximately 5, was heat-labile, and was destroyed by treatment with trypsin but not with deoxyribonuclease or ribonuclease. Seventeen of 21 patients with benign prostatic hyperplasia and three patients with prostatic carcinoma had 1 to 40 fmoles of specific R 5020-binding sites per mg of cytosol protein. One sample of normal prostatic tissue did not contain significant amounts of progesting receptor. Tissue specimens removed by transvesical adenoma enucleation displayed a larger number of specific R 5020-binding sites than electroresected specimens. The progestin receptor in hyperplastic prostate may be involved in the mechanism of the action of progestins used in the medical treatment of benign prostatic hyperplasia. Quantitation of progestin receptor in cancer of the prostate may form part of the basis of a predictive test program for endocrine therapy of prostatic malignancy.
 ...
PMID:Demonstration of a progestin receptor in human benign prostatic hyperplasia and prostatic carcinoma. 7 18

17 alpha-Acetoxy-6 alpha-methylprogesterone (medroxy-progesterone acetate, MPA) in doses of 50 mg followed 4 weeks later by an additional 100 mg was i.m. injected in 5 adult normal female monkeys. Serum levels of MPA, progesterone, estradiol-17-beta and LH were determined every other day for a period of 8 weeks then weekly for 8 months. Peak values of serum MPA were detected 2 weeks postinjection followed by a gradual decline to undetectable levels after variable periods ranging from 125 to 225 days. The drug, in the doses used, caused inhibition of LH and estradiol surges and suppression of progesterone for more than 6 months. The return of menstrual cyclicity preceded the return of ovulatory cyclicity. Menstrual cyclicity occurred while the drug was still detectable in the blood. The probable site of action of the drug is discussed.
 ...
PMID:Medroxyprogesterone acetate: peripheral serum levels and its effects on pituitary and ovarian functions in the rhesus monkey. 10 56

The inhibitory effect of some gestagens and calusterone on the binding of estradiol-17beta to its specific uterine receptors has been investigated in intact rats. Progesterone, medrogestone, clogestone, medroxyprogesterone acetate and calusterone reduce the specific estradiol-receptor interaction in vitro; this effect is dose-dependent and does not differ significantly from 1 drug to the other. A more relevant decrease in the amount of estradiol-17beta bound to specific receptors has been observed with calusterone. Progesterone, clogestone, medrogestone, medroxyprogesterone acetate and calusterone given orally induce a marked decrease (between 30 and 70% depending on the dose) in the binding capacity of estradiol-17beta to specific uterine receptors in vivo. Results from a Scatchard plot analysis suggest that the interference with the binding of estradiol-17beta caused by both progestogens and calusterone is due to a noncompetitive interaction.
 ...
PMID:Interference of gestagens and androgens with rat uterine oestrogen receptors. 14 13

Studies were made on the effect of concomitant administration of dehydroepiandrosterone acetate (DHA-Ac) with progesterone on decidual growth in the rat. Virgin female rats of Wistar strain weighing about 250 g were used. Daily vaginal smears were recorded and, during the time of vaginal cornification, the animals were made pseudopregnant by tapping the uterine cervix. Day 1 of the pseudopregnancy was designated as the day that the vaginal smears contained primarily leucocytes. On day 4 of the pseudopregnancy, each animal was laparotomized midventrally, and bilateral ovariectomy and scratching of the uterine endometrium were performed. Progesterone, alone or in combination with DHA-Ac, was injected from day 4 of the pseudopregnancy (immediately after ovariectomy) through day 8. On day 9 of the pseudopregnancy all animals were killed. The weights of the uterus, and the deciduoma-inducing score, etc, were estimated. Massive deciduomata weighing 2768 +/- 84 mg per uterus were induced in intact pseudopregnant rats. Treatment with 2 mg progesterone evoked maximal responses of only 754 +/- 101 mg. The concomitant administration of 20 mg DHA-Ac with 2 mg progesterone reproduced the decidual weight observed in intact rats, but 2.5 mg or 5 mg DHA-Ac in combination with 2 mg progesterone was only slightly effective. The weights of the uterus, the deciduoma-inducing score, the histological findings, and the effects of the DHA-Ac were discussed.
 ...
PMID:[The effect of concomitant administration of dehydroepiandrosterone with progesterone on decidual growth in the rat (author's transl)]. 14 79

High dosage MAP (medroxyprogesterone acetate) was used in the treatment of very advanced breast cancer. 25 patients were included in the study all of whom had measurable lesions which had been unsuccessfully treated by other methods, hormonal or combination chemotherapy. Tables present information on previous treatments, results of pre-MAP therapy examinations, and results of post-MAP therapy examinations. Treatment dosage is explained. Results with this high MAP-dosage therapy compare favorably with the rate of remission obtained through other primary hormonal therapies by other researchers. Promising results without noteworthy adverse effects were obtained; remissions, however, were short. 7 of the 25 had partial remission with a median duration of 5+ months. Another 7 patients obtained a stationary status of the disease. Even some patients who had not responded previously to Tamoxifen achieved partial remission with MAP therapy, indicating that the MAP does not operate directly on the tumor cells. The incidence of partial remissions was not adversely affected by previous combination chemotherapy and hormonal treatment. Acceptability of the treatment was good.
 ...
PMID:High dose medroxyprogesterone-acetate treatment in advanced mammary carcinoma. A phase II investigation. 16 70


1 2 3 4 5 6 7 8 9 10 Next >>